Eli Lilly earnings selloff brings buying opportunity, says JPMorgan
The Fly

Eli Lilly earnings selloff brings buying opportunity, says JPMorgan

JPMorgan analyst Chris Schott views the post-earnings weakness in Eli Lilly (LLY) shares as a buying opportunity. While the results missed expectations, mostly on wholesaler destocking for Mounjaro and Zepbound, underlying volume trends for Eli Lilly’s business remain healthy, the analyst tells investors in a research note. The firm says that with capacity ramping and Lilly now increasing its demand generating activities as a result, it anticipates a “significant step up” in Q4 sales. JPMorgan keeps an Overweight rating on the shares with a $1,100 price target

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App